22nd Century Group (Nasdaq: XXII) Summary
VLN® Cig-a-rettes — Proven, Ready & In The Market
- Science validated, clinical proof in market
- Product strategy launched + strengthened through partner brands (VLN® inside)
Growth Engine in Motion
- Portfolio built for cross-sell + gradual expansion through 2026 into 2027
- Fully aligned with the FDA’s low nicotine mandate
- Market Leader in a new Low Nicotine Content category
Innovation That Doesn’t Stop
- Ongoing R&D in low-nicotine strains + reduced-nicotine products
- Expanding through branded growth, licensing, and partnerships
Key to Success
- Scaling distribution + accelerating sell-through = industry leadership.
- Belief that VLN® will be a big part of the future of to-bac-co.
Grab Sources And More Here: XXII Website. XXII Presentation. -----
And as we mentioned earlier, (Nasdaq: XXII) is backed by multiple potential catalysts. Check them out:
#1. XXII Potential Catalyst - A Very Low Float May Help Establish An Environment For Heightened Volatility Potential.
According to info from the Yahoo Finance website, XXII has a relatively low float.
The website reports this profile to have roughly 4.07Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides positive news during the first half of 2026, could it help provide a breakout spark when paired with this volatility potential? -----
#2. XXII Potential Catalyst - Multiple Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing.
At 12:00PM EST Thursday, Barchart was reporting XXII to possess several oversold leaning technical indicators.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here are the technicals to pay close attention to (as of 12:00PM EST Thursday):
- 9-Day Relative Strength Index: 19.87%
- 14-Day Relative Strength Index: 19.22%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic %D: 11.63%
As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely especially since they're still displaying oversold tendencies after XXII's vertical chart growth this week. -----
#3. XXII Potential Catalyst - The FDA Has Filed The Company's VLN® MRTP Renewal Applications For Scientific Review.
22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review
FDA filing covers renewal applications for VLN® King and VLN® Menthol King, the first combusted cig-a-rettes authorized as Modified Risk To-bac-co Products, as 22nd Century advances its regulatory pathway for continued modified risk marketing status
MOCKSVILLE, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a to-bac-co harm reduction company focused on reduced nicotine innovation, today highlighted that the U.S. Food and Drug Administration has filed for scientific review two Modified Risk To-bac-co Product, or MRTP, renewal applications for the Company’s VLN® King and VLN® Menthol King combusted, filtered cig-a-rettes. The FDA filing marks an important step in the regulatory process for the continued marketing of these products with authorized modified risk claims.
VLN® King and VLN® Menthol King were originally granted MRTP exposure modification orders by the FDA in December 2021, making them the first combusted cig-a-rettes ever authorized as MRTPs. Those orders are set to expire in December 2026 unless renewed, and the current review process is intended to support continued modified risk marketing status beyond that date.
“We are pleased that the FDA has filed our VLN® MRTP renewal applications for scientific review, an important procedural step in the renewal process for the first and only combustible cig-a-rettes authorized as modified risk to-bac-co products,” said Larry Firestone, Chief Executive Officer of 22nd Century Group. “We believe this development reflects the strength of the scientific and regulatory foundation supporting VLN®, and we remain focused on working through the FDA review process responsibly, transparently and in full compliance with all applicable requirements as we continue advancing our reduced-nicotine platform for adult smokers.”
...
Read the full article here. -----
#4. XXII Potential Catalyst - The Company Signs A New Testing Services Agreement To Help Focus On Confirming Commercial Viability.
22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University
MOCKSVILLE, N.C., April 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a to-bac-co products company focused on nicotine reduction and plant biotechnology, today announced corporate updates regarding a new testing services agreement with North Carolina State University aimed at validating to-bac-co varieties featuring improved leaf quality and increased crop yields with the same low-nicotine content.
The initiative builds upon 22nd Century’s proprietary reduced nicotine content technology platform, which utilizes advanced plant breeding and biotechnology to reduce nicotine content in to-bac-co to minimally addictive levels. The Company’s reduced nicotine to-bac-co is the foundation of its FDA-authorized VLN® combustible cig-a-rette products and represents years of scientific development in plant genetics and regulatory science.
The newly signed testing services agreement will focus on confirming commercial viability of to-bac-co varieties incorporating 22nd Century’s patented low-nicotine genetics to increase yield, improve leaf quality and consistency, support more efficient, scalable production, ensure long-term sustainability for contracted growers, and preserve the integrity of the Company’s reduced-nicotine characteristics.
Larry Firestone, Chief Executive Officer of 22nd Century Group, stated, “This is about producing robust reduced nicotine to-bac-co plants from the ground up. As policymakers and regulators around the world continue to focus on health, wellness, and sensible standards that reduce nicotine dependence, we believe our VLN® products are in prime position to support that global dialogue. Our products and technology directly align with the U.S. FDA’s proposed maximum nicotine standard and broader global public health objectives aimed at lowering addiction levels across the U.S. and around the world. This important research only further strengthens our commitment and consistent track record of demonstrating commercial viability. We believe our reduced nicotine VLN® cig-a-rette products are the best alternative to highly addictive standard cig-a-rettes and other nicotine products in the market if the FDA’s policies were implemented.”
“By continuing to partner with North Carolina State University, one of the nation’s premier agricultural research institutions, we are investing in next-generation plant science to further strengthen our proprietary to-bac-co genetics. Improving the yield and quality of low-nicotine to-bac-co is not just good agronomy, it strengthens American farming, enhances supply chain resilience, and ensures that our reduced nicotine platform can scale reliably and sustainably. We are combining innovation, regulatory alignment, and agricultural excellence to deliver a product designed for the future of nicotine policy and adult consumer choice.”
...
Read the full article here. -----
#5. XXII Potential Catalyst - The Company Targets A Multi-Bn Dollar Market With Its 100mm VLN® Product Initiative.
22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82Bn U.S. Cig-a-rette Market with 100mm VLN® Product Initiative
Company to Pursue Additional PMTA Submissions, Building on Its Status as the Only Holder of an FDA-Authorized Low Nicotine Combustible Cig-a-rette Branded as VLN® Products
Expanded PMTA Portfolio and Licensing Strategy Designed to Address Wider Consumer Preference and Unlock Further Retail Penetration Opp's
MOCKSVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a to-bac-co products company focused on reducing the harms of smoking through nicotine reduction, today announced an update on the advancement of a 100mm VLN® reduced nicotine content cig-a-rette.
...
Previously announced as “Operation 100” in 2025, the Company’s research and development team has completed product prototyping and initial analytical evaluations required for advancing to the next phase of regulatory submissions. 22nd Century Group believes that introducing a 100mm VLN® reduced nicotine content cig-a-rette — alongside its existing authorized 84mm king size VLN® products — will expand access to reduced nicotine alternatives in the familiar form factors preferred by adult smokers.
Notably, 22nd Century Group currently holds the only FDA-issued Premarket To-bac-co Product Application (PMTA) authorization for a combustible reduced nicotine content cig-a-rette, its VLN® king size products. Building on this foundation, the Company is preparing a second PMTA application for authorization from the FDA for its new 100mm VLN® cig-a-rette. Management believes its prior PMTA experience, scientific data package, and regulatory engagement have positioned the Company to efficiently advance the 100mm submission process.
...
“Our attitude at 22nd Century is that it would be preferable if the FDA did not need to impose a mandate on low-nicotine cig-a-rettes. Instead, we believe progress can be achieved by continuing to expand our presence in the to-bac-co retail market with our own brands and licensed partner brands, allowing consumers across the U.S. and eventually around the world to access VLN® products through normal market choice.
We are open to licensing our low-nicotine technology more broadly within the industry, which we believe could significantly accelerate efforts to reduce smoking-related harm in a relatively short period of time.
We envision a future where virtually any brand a consumer chooses could offer a VLN® SKU on the shelf, similar to what we have already accomplished with Pinnacle VLN® and Smoker Friendly VLN®. Today, we believe we offer a compelling solution for adult smokers who value the ritual of lighting up and relaxing with a cig-a-rette, while seeking a reduced-nicotine alternative,” stated Larry Firestone, Chief Executive Officer of 22nd Century Group.
...
Read the full article here. -----
(Nasdaq: XXII) Recap - These 5 Potential Catalysts Just Hit Our Radar
#1. A Very Low Float May Help Establish An Environment For Heightened Volatility Potential.
#2. Multiple Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing.
#3. The FDA Has Filed The Company's VLN® MRTP Renewal Applications For Scientific Review.
#4. The Company Signs A New Testing Services Agreement To Help Focus On Confirming Commercial Viability.
#5. The Company Targets A Multi-Bn Dollar Market With Its 100mm VLN® Product Initiative. -----
We're officially kicking-off coverage on 22nd Century Group, Inc. (Nasdaq: XXII).
Be on the lookout for updates heading out shortly. Talk soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 05/14/2026 and ending on 05/15/2026 to publicly disseminate information about (XXII:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid sixty seven thousand five hundred USD ("Funds"). These Funds were part of the seventeen thousand five hundred USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (XXII:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/xxii-qfkdx/#details |
